Prostate Cancer Radiotherapy: Bone Metastatic Burden Linked to Survival

In patients receiving radiotherapy for newly diagnosed metastatic prostate cancer, bone metastasis count and location are associated with overall and failure-free survival, according to an exploratory analysis of the phase 3 STAMPEDE trial. "Prostate radiotherapy improves survival in men with low-burden metastatic prostate cancer," write the investigators in their publication in JAMA Oncology, led by first author Adnan Ali, MBBS, Clinical Research Fellow in the Division of Cancer Sciences at the...

Pharyngeal Cancer: Fewer Acute Toxicities With Intensity-Modulated Proton Therapy

In patients with pharyngeal cancer, intensity-modulated proton therapy (IMPT) with a model-based approach was associated with a lower rate of acute toxicities, especially dysphagia, compared with those receiving intensity-modulated X-ray therapy (IMXT), according to results of a retrospective analysis now published in the Journal of Radiation Research. "Radiation therapy is the mainstay treatment for head and neck cancer," write the investigators, led by Koichi Yasuda, MD, PhD, Assistant Profess...

Radiotherapy Dose Exposure Linked to Major Adverse Cardiac Events in NSCLC

In patients with locally advanced non-small cell lung cancer (NSCLC) treated with thoracic radiotherapy, a greater left anterior descending (LAD) coronary artery dose exposure was associated with an increased risk of major adverse cardiac events (MACE) and all-cause mortality, particularly in patients with baseline coronary heart disease (CHD), according to results of a cohort study now published in JAMA Oncology. "Development of cardiac adverse events is a well-recognized risk following radioth...

New Durvalumab Dosing Schedule Approved for Urothelial Carcinoma and Non-Small Cell Lung Cancer

 The FDA recently approved new doses of durvalumab (Imfinzi®, AstraZeneca) for the treatment of patients with previously treated advanced urothelial carcinoma and unresectable stage III non-small cell lung cancer. "Durvalumab, a selective, high-affinity, engineered human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, is approved in the US, Japan, and several other countries for the treatment of patients with unresectable, stage III NSCLC whose disease has not progressed following conc...

Triple-Negative Breast Cancer: Which is Better, Adjuvant Chemotherapy or Radiotherapy?

In patients who have been diagnosed with T1 N0 M0 triple-negative breast cancer (TNBC), age plays a role in whether chemotherapy or radiotherapy will lead to better outcomes for overall survival and breast cancer–specific survival (BCSS), according to the results of a cohort study now published in JAMA Network Open. The investigators, led by Zhen Zhai, MD, of the Department of Breast Surgery in the First Affiliated Hospital in the College of Medicine at Zhejiang University in Hangzhou, China, en...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts